Tumor Suppression by Phospholipase C-β3 via SHP-1-Mediated Dephosphorylation of Stat5

Cancer Cell

Volumn 16, Issue 2, 2009, Pages 161-171

  Xiao, Wenbin ^a   Hong, Hong ^a   Kawakami, Yuko ^a   Kato, Yuko ^b   Wu, Dianqing ^c   Yasudo, Hiroki ^a   Kimura, Akiko ^d   Kubagawa, Hiromi ^e   Bertoli, Luigi F ^g   Davis, Randall S ^f   Chau, Luan A ^h   Madrenas, Joaquin ^h   Hsia, Cyrus C ^h   Xenocostas, Anargyros ^h   Kipps, Thomas J ⁱ   Hennighausen, Lothar ^d   Iwama, Atsushi ^b   Nakauchi, Hiromitsu ^j   Kawakami, Toshiaki ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e University of Alabama at Birmingham   (United States)

^f University of Alabama at Birmingham   (United States)

^g Brookwood Medical Center Birmingham   (United States)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

more..

Author keywords

CELLCYCLE

Indexed keywords

PHOSPHOLIPASE C BETA3; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT5 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ERYTHROLEUKEMIA CELL; FIBROBLAST; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LYMPHOMA; MALIGNANT TRANSFORMATION; MOUSE; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

MUS;

EID: 67651152910     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.05.018     Document Type: Article

References (54)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., and Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318 (1985) 533-538
2. Alexander W.S., and Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22 (2004) 503-529
3. Bach T.L., Chen Q.M., Kerr W.T., Wang Y., Lian L., Choi J.K., Wu D., Kazanietz M.G., Koretzky G.A., Zigmond S., et al. Phospholipase cbeta is critical for T cell chemotaxis. J. Immunol. 179 (2007) 2223-2227
4. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
5. Benekli M., Baer M.R., Baumann H., and Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 101 (2003) 2940-2954
6. Boxer L.M., and Dang C.V. Translocations involving c-myc and c-myc function. Oncogene 20 (2001) 5595-5610
7. Bunting K.D., Bradley H.L., Hawley T.S., Moriggl R., Sorrentino B.P., and Ihle J.N. Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood 99 (2002) 479-487
8. Cain J.A., Xiang Z., O'Neal J., Kreisel F., Colson A., Luo H., Hennighausen L., and Tomasson M.H. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood 109 (2007) 3906-3914
9. Camps M., Carozzi A., Schnabel P., Scheer A., Parker P.J., and Gierschik P. Isozyme-selective stimulation of phospholipase C-beta 2 by G protein beta gamma-subunits. Nature 360 (1992) 684-686
10. Choudhary C., Brandts C., Schwable J., Tickenbrock L., Sargin B., Ueker A., Bohmer F.D., Berdel W.E., Muller-Tidow C., and Serve H. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 110 (2007) 370-374
11. Cui Y., Riedlinger G., Miyoshi K., Tang W., Li C., Deng C.X., Robinson G.W., and Hennighausen L. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol. Cell. Biol. 24 (2004) 8037-8047
12. Emanuel P.D., Bates L.J., Castleberry R.P., Gualtieri R.J., and Zuckerman K.S. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77 (1991) 925-929
13. Frohling S., Scholl C., Gilliland D.G., and Levine R.L. Genetics of myeloid malignancies: pathogenetic and clinical implications. J. Clin. Oncol. 23 (2005) 6285-6295
14. Ilaria Jr. R.L., Hawley R.G., and Van Etten R.A. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 93 (1999) 4154-4166
15. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
16. Jiao H., Berrada K., Yang W., Tabrizi M., Platanias L.C., and Yi T. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol. Cell. Biol. 16 (1996) 6985-6992
17. Kato Y., Iwama A., Tadokoro Y., Shimoda K., Minoguchi M., Akira S., Tanaka M., Miyajima A., Kitamura T., and Nakauchi H. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J. Exp. Med. 202 (2005) 169-179
18. Katz A., Wu D., and Simon M.I. Subunits beta gamma of heterotrimeric G protein activate beta 2 isoform of phospholipase C. Nature 360 (1992) 686-689
19. Klingmuller U., Lorenz U., Cantley L.C., Neel B.G., and Lodish H.F. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80 (1995) 729-738
20. Kogan S.C., Ward J.M., Anver M.R., Berman J.J., Brayton C., Cardiff R.D., Carter J.S., de Coronado S., Downing J.R., Fredrickson T.N., et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100 (2002) 238-245
21. Kondo M., Wagers A.J., Manz M.G., Prohaska S.S., Scherer D.C., Beilhack G.F., Shizuru J.A., and Weissman I.L. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu. Rev. Immunol. 21 (2003) 759-806
22. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (2005) 1779-1790
23. Kyba M., Perlingeiro R.C., Hoover R.R., Lu C.W., Pierce J., and Daley G.Q. Enhanced hematopoietic differentiation of embryonic stem cells conditionally expressing Stat5. Proc. Natl. Acad. Sci. USA 100 Suppl 1 (2003) 11904-11910
24. Lee S.B., Shin S.H., Hepler J.R., Gilman A.G., and Rhee S.G. Activation of phospholipase C-beta 2 mutants by G protein alpha q and beta gamma subunits. J. Biol. Chem. 268 (1993) 25952-25957
25. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
26. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3 (2002) 651-662
27. Li Z., Jiang H., Xie W., Zhang Z., Smrcka A.V., and Wu D. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287 (2000) 1046-1049
28. Lilly M., and Kraft A. Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res. 57 (1997) 5348-5355
29. Matsumoto A., Masuhara M., Mitsui K., Yokouchi M., Ohtsubo M., Misawa H., Miyajima A., and Yoshimura A. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89 (1997) 3148-3154
30. Mui A.L., Wakao H., O'Farrell A.M., Harada N., and Miyajima A. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J. 14 (1995) 1166-1175
31. Mullighan C.G., Goorha S., Radtke I., Miller C.B., Coustan-Smith E., Dalton J.D., Girtman K., Mathew S., Ma J., Pounds S.B., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446 (2007) 758-764
32. Nakahira M., Tanaka T., Robson B.E., Mizgerd J.P., and Grusby M.J. Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity 26 (2007) 163-176
33. Nosaka T., Kawashima T., Misawa K., Ikuta K., Mui A.L., and Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 18 (1999) 4754-4765
34. O'Shea J.J., Gadina M., and Schreiber R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 Suppl (2002) S121-S131
35. Paling N.R., and Welham M.J. Role of the protein tyrosine phosphatase SHP-1 (Src homology phosphatase-1) in the regulation of interleukin-3-induced survival, proliferation and signalling. Biochem. J. 368 (2002) 885-894
36. Passegue E., Wagner E.F., and Weissman I.L. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119 (2004) 431-443
37. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
38. Rhee S.G. Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. 70 (2001) 281-312
39. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., and Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6 (2004) 1-6
40. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 340 (1999) 1330-1340
41. Sawyers C.L., McLaughlin J., and Witte O.N. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med. 181 (1995) 307-313
42. Schindler C., Levy D.E., and Decker T. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282 (2007) 20059-20063
43. Schuringa J.J., Chung K.Y., Morrone G., and Moore M.A. Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J. Exp. Med. 200 (2004) 623-635
44. Schwaller J., Parganas E., Wang D., Cain D., Aster J.C., Williams I.R., Lee C.K., Gerthner R., Kitamura T., Frantsve J., et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell 6 (2000) 693-704
45. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 19 (2000) 2638-2644
46. Shultz L.D., Schweitzer P.A., Rajan T.V., Yi T., Ihle J.N., Matthews R.J., Thomas M.L., and Beier D.R. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73 (1993) 1445-1454
47. Singer A.U., Waldo G.L., Harden T.K., and Sondek J. A unique fold of phospholipase C-beta mediates dimerization and interaction with G alpha q. Nat. Struct. Biol. 9 (2002) 32-36
48. Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J.K., Trotta R., Wlodarski P., Perrotti D., Chan T.O., et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16 (1997) 6151-6161
49. Snow J.W., Abraham N., Ma M.C., Abbey N.W., Herndier B., and Goldsmith M.A. STAT5 promotes multilineage hematolymphoid development in vivo through effects on early hematopoietic progenitor cells. Blood 99 (2002) 95-101
50. Tanaka T., Soriano M.A., and Grusby M.J. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity 22 (2005) 729-736
51. Tsui H.W., Siminovitch K.A., de Souza L., and Tsui F.W. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat. Genet. 4 (1993) 124-129
52. Warmuth M., Kim S., Gu X.J., Xia G., and Adrian F. Ba/F3 cells and their use in kinase drug discovery. Curr. Opin. Oncol. 19 (2007) 55-60
53. Xiao W., Hong H., Kawakami Y., Lowell C.A., and Kawakami T. Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. J. Clin. Invest. 118 (2008) 924-934
54. Yoshimura A., Ichihara M., Kinjyo I., Moriyama M., Copeland N.G., Gilbert D.J., Jenkins N.A., Hara T., and Miyajima A. Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway. EMBO J. 15 (1996) 1055-1063